SAR443765 / LUNSEKIMIG, Matched Placebo to Test clinical trials

A Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 3 subcutaneous dose regimens of lunsekimig (SAR443765) in adult participants with moderate to-severe atopic dermatitis

This study is testing a new medicine called lunsekimig for adults with moderate to severe eczema. We want to see how well it works to reduce eczema symptoms and if it's safe. Participants will receive either the new medicine or a dummy medicine.